antimicrobial-peptide-ib-367 and Gram-Positive-Bacterial-Infections

Iseganan (IB-367) is a protegrin under development by IntraBiotics, as part of a larger protegrin program, for the potential treatment of oral mucositis, a frequent side effect of anticancer therapies. The company is developing three formulations of the drug: A rinse for the potential treatment of mucositis, an aerosolized liquid for the potential treatment of respiratory infection and a gel formulation for the potential treatment of pneumonia [376325]. Iseganan kills a broad-spectrum of bacteria and fungi, including those resistant to conventional antimicrobial drugs, by attaching to and destroying the integrity of the lipid cell membrane [241594]. Until August 1999, Pharmacia & Upjohn was a codeveloper of iseganan. IntraBiotics re-acquired the global rights to iseganan in December 1999, and both companies agreed to terminate the collaboration [335766]. In May 2000, analysts at SG Cowen predicted the drug's potential market at US $100 to US $200 million [376325].

Topics: Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Industry; Drugs, Investigational; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Mouth Mucosa; Peptides; Proteins; Randomized Controlled Trials as Topic; Stomatitis; Structure-Activity Relationship; Treatment Outcome